Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
12/2010
12/02/2010US20100303867 a composition comprising a notch ligand and an allergenb or allergen bystander antigen
12/02/2010US20100303843 RECOMBINANT ALLERGEN WITH REDUCED lgE BINDING BUT UNDIMINISHED T-CELL ANTIGENICITY
12/02/2010US20100303832 Genes and polymorphisms associated with amd
12/02/2010US20100303830 PREVENTION AND TREATMENT OF OTITIS MEDIA USING IgA ENRICHED MILK
12/02/2010US20100303822 Polypeptides from non-typeable haemophilus influenzae
12/02/2010US20100303782 Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
12/02/2010US20100303768 Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
12/02/2010US20100303758 Novel Glucocorticoid Receptor Agonists
12/02/2010CA2763469A1 Antigen-binding proteins
12/02/2010CA2762620A1 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors
12/02/2010CA2760757A1 Compositions and methods for antibodies targeting complement protein c3b
12/01/2010EP2256105A1 Novel tetrahydroisoquinoline derivative
12/01/2010EP2255788A1 Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye
12/01/2010EP2254860A1 Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the b2 adrenergic receptor
12/01/2010EP2254577A1 Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
12/01/2010EP2254572A2 Compounds that enhance atoh-1 expression
12/01/2010EP2254567A2 Novel use of zinc n-acetyltaurinate
12/01/2010EP2254412A1 Macrocyclic lactone compounds and methods for their use
12/01/2010EP1926483B1 Treatment of autoimmune diseases
12/01/2010EP1711190B1 Agent for treating inflammatory diseases
12/01/2010CN1939534B Externally-applied preparation containing human growth incretion or human granular leukocyte macrophage stimulus factor for treating injury ulceration
12/01/2010CN1646154B Albumin-fused anti-angiogenesis peptides
12/01/2010CN101903045A Pharmaceutical composition for treatment of cataract
12/01/2010CN101897975A Chitosan-Math1 gene nanoparticle and application thereof in treatment of deafness
12/01/2010CN101897970A Compositions and methods for treating diabetes
12/01/2010CN101897958A Superoxide dismutase eye drops and preparation method thereof
12/01/2010CN101897949A Ophthalmic medicament composition for forming low-irritation transparent emulsion formulation for surface immune adjustment and inflammation reduction of relevant tissue of eyes or eye periphery
12/01/2010CN101897896A Chinese medicinal composition for treating cataract and medicinal preparation and preparation method thereof
12/01/2010CN101897859A Chinese medicinal preparation for treating Meniere's syndrome
12/01/2010CN101897856A Traditional Chinese medicine pills for treating deafness
12/01/2010CN101897831A Method for extracting and separating medlar total alkaloids from medlar
12/01/2010CN101897829A Medicinal composition with function of alleviating visual fatigue and preparation method thereof
12/01/2010CN101897809A Traditional Chinese medicine for treating diabetic retinopathy
12/01/2010CN101897801A Chinese medicinal pills for treating tympanitis
12/01/2010CN101897747A Traditional Chinese medicinal health care product used for alleviating eye fatigue and preparation method thereof
12/01/2010CN101897724A Method for producing a soft tissue filler and method for producing an adipose tissue transplant
12/01/2010CN101897704A Compositions containing alpha-2-adrenergic agonist components
12/01/2010CN101897698A Sugar-lowering drug composition containing vildagliptin and B vitamins and application thereof
12/01/2010CN101897697A Sugar-lowering drug composition and application
12/01/2010CN101897696A Sugar-lowering drug composition and application thereof
12/01/2010CN101897671A Xylitol micro pill preparations and preparation method thereof
12/01/2010CN101897662A Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
12/01/2010CN101897378A Antipyretic tea for removing liver-fire
12/01/2010CN101391071B Traditional Chinese medicine for treating diabetic ocular fundus diseases
12/01/2010CN101219143B Use of anisodine in preparing medicament for treating amblyopia
12/01/2010CN101077150B Bean product with eyesight-improving health care function and its manufacturing method
11/2010
11/30/2010US7842714 A topical aqeous opthalmic solution containing ketorolac tromethamine, carboxymethyl cellulose, medium viscosity, carboxymethyl cellulose, high viscosity, NaCl, sodium citrate dihydrate, a buffer selected from NaOH and HCl to adjust pH to about 6, and water;
11/30/2010CA2519938C Prostaglandin analogs as ep4 receptor agonists
11/30/2010CA2456817C Alkyne-aryl-naphthyridin-4 (1h)-one derivatives as type iv phosphodiesterase inhibitor
11/25/2010WO2010135621A1 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
11/25/2010WO2010135579A1 Fluorinated diaryl urea derivatives
11/25/2010WO2010135404A1 Ep2 receptor agonist from non-prostanoid structures designed as pge2 antagonists
11/25/2010WO2010134067A1 A3 adenosine receptor agonists for the reduction of intraocular pressure
11/25/2010WO2010133882A1 Disaccharin, difumaric acid, di-l-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4- (dimethylamin0)butyl 2- (4- ( (2-amino-4-methyl-6- (pentylamino) pyrimidin- 5 -yl) methyl) phenyl)acetate
11/25/2010WO2010107991A3 Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
11/25/2010WO2010047803A3 A method for the treatment of proliferative disorders of the eye
11/25/2010US20100299765 Modalities for the treatment of degenerative diseases of the retina
11/25/2010US20100298446 Actinically-crosslinkable siloxane-containing copolymers
11/25/2010US20100298443 Methods and compositions for treating ophthalmic conditions with retinyl derivatives
11/25/2010US20100298441 Titration package for neramexane and its use in the treatment of an inner ear disorder
11/25/2010US20100298440 1-aminocyclohexane derivatives for the treatment of hearing loss
11/25/2010US20100298436 EP2 Agonist from Non-Prostanoid Structures Designed as PGE2 Antagonists
11/25/2010US20100298408 Oligonucleotide Compositions with Enhanced Efficiency
11/25/2010US20100298395 Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
11/25/2010US20100298381 Gamma secretase modulators
11/25/2010US20100298348 Method of Decreasing Ubiquitylated Protein Levels
11/25/2010US20100298344 Polycationic Compounds And Uses Thereof
11/25/2010US20100298337 Organic Compounds
11/25/2010US20100298335 Preparations and Methods for Ameliorating or Reducing Presbyopia
11/25/2010US20100298330 Haloallylamine inhibitors of ssao/vap-1 and uses therefor
11/25/2010US20100298328 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes
11/25/2010US20100298326 Carboxamide compounds and their use as calpain inhibitors
11/25/2010US20100298325 Pyridine derivatives for the treatment of amyloid-related diseases
11/25/2010US20100298310 Thiazole Derivatives as Kinase Inhibitors
11/25/2010US20100298309 Tricyclic triazolic compounds
11/25/2010US20100298286 Organic Compounds
11/25/2010US20100298282 Treatment of Ocular Conditions and the Side-Effects of Glucocorticoids
11/25/2010US20100298273 Lipid mixture for infant nutrition
11/25/2010US20100298263 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect
11/25/2010US20100298252 Methods and compositions for ophthalmic treatment of fungal and bacterial infections
11/25/2010US20100298248 Biologically active macrolides, compositions, and uses thereof
11/25/2010US20100298225 Peptide gap junction modulators
11/25/2010US20100297256 Methods and compositions for inhibiting integrins using tellurium-containing compounds
11/25/2010US20100297234 Method of using an extracellular matrix to enhance cell transplant survival and differentiation
11/25/2010US20100297202 Planar antenna and method of manufacturing the same
11/25/2010US20100297193 Methods of therapeutic treatment of eyes
11/25/2010US20100297181 AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
11/25/2010US20100297121 Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
11/25/2010US20100297100 Composition for Treating Retinopathy or Glaucoma Comprising Thrombin Derived Peptides
11/25/2010US20100297084 method for transducing cells with primary cilia
11/25/2010US20100297058 Prebiotic composition
11/25/2010US20100297013 Humanized antibody
11/25/2010US20100297012 Humanized antibody
11/25/2010CA2761954A1 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
11/25/2010CA2761499A1 A3 adenosine receptor agonists for the reduction of intraocular pressure
11/25/2010CA2760765A1 Disaccharin, difumaric acid, di-1-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4- (dimethylamino)butyl 2- (4- ( (2-amino-4-methyl-6- (pentylamino) pyrimidin-5-yl) methyl) phenyl)acetate
11/24/2010EP2253327A1 Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound
11/24/2010EP2253325A1 Agent for enhancing corneal epithelial barrier function
11/24/2010EP2253323A1 Anti-allergic agent
11/24/2010EP2253322A1 Method and composition containing latanoprost for treating ocular hypertension and glaucoma
1 ... 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 ... 531